BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27826616)

  • 21. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
    Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
    Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens.
    Haley L; Parimi V; Jiang L; Pallavajjala A; Hardy M; Yonescu R; Morsberger L; Stinnett V; Long P; Zou YS; Gocke CD
    J Mol Diagn; 2021 Oct; 23(10):1343-1358. PubMed ID: 34358677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
    Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories.
    Mendez P; Dang J; Kim JW; Lee S; Yoon JH; Kim T; Sailey CJ; Jablons DM; Kim IJ
    Int J Oncol; 2016 Jul; 49(1):235-42. PubMed ID: 27121194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
    Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
    Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens.
    Hadd AG; Houghton J; Choudhary A; Sah S; Chen L; Marko AC; Sanford T; Buddavarapu K; Krosting J; Garmire L; Wylie D; Shinde R; Beaudenon S; Alexander EK; Mambo E; Adai AT; Latham GJ
    J Mol Diagn; 2013 Mar; 15(2):234-47. PubMed ID: 23321017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.
    Vanni I; Coco S; Truini A; Rusmini M; Dal Bello MG; Alama A; Banelli B; Mora M; Rijavec E; Barletta G; Genova C; Biello F; Maggioni C; Grossi F
    Int J Mol Sci; 2015 Dec; 16(12):28765-82. PubMed ID: 26633390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
    Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
    Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
    Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A
    Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
    Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
    Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amplicon-Based NGS Panels for Actionable Cancer Target Identification in Follicular Cell-Derived Thyroid Neoplasia.
    Madsen MB; Kiss K; Cilius Nielsen F; Bennedbæk FN; Rossing M
    Front Endocrinol (Lausanne); 2020; 11():146. PubMed ID: 32265839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
    Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
    Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients.
    Jiang R; Zhang B; Teng X; Hu P; Xu S; Zheng Z; Liu R; Tang T; Ye F
    Sci Rep; 2020 Feb; 10(1):2070. PubMed ID: 32034196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for
    Venetis K; Pepe F; Munzone E; Sajjadi E; Russo G; Pisapia P; Ivanova M; Bonizzi G; Vacirca D; Rappa A; Ranghiero A; Taormina SV; Viale G; Troncone G; Barberis M; Guerini-Rocco E; Malapelle U; Fusco N
    Cells; 2022 Nov; 11(22):. PubMed ID: 36428975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
    Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
    BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.